+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost estimates for treatment of cardiac ischemia study



Cost estimates for treatment of cardiac ischemia study



American Journal of Cardiology 84(11): 1311-1316



Costs for management of myocardial ischemia are enormous, yet comparison cost and outcome data for various ischemia treatment strategies from randomized trials are lacking and will require cost and resource utilization data from a large prospective trial. The Asymptomatic Cardiac Ischemia Pilot provided feasibility data for planning such a trial and an opportunity to estimate the long-term costs of different treatment strategies. Economic implications for ischemia management were compared in 558 patients with stable coronary artery disease and myocardial ischemia during both stress testing and daily life. Participants were randomized to 3 different initial treatment strategies and followed for 2 years. Based on cost trends over follow-up, costs for subsequent care were estimated. As expected, due to initial procedural costs, at 3 months, estimated costs for revascularization were approximately 10 times greater than costs for a medical care strategy. Extrapolated costs for anticipated resource consumption for care beyond 2 years, however, were approximately 2 times greater for an initial medical care strategy than for initial revascularization. This was due to increased need for drugs and hospitalizations for both late revascularizations and other ischemia-related events. Estimated costs for anticipated care in the medical strategies reached the anticipated cost of the revascularization strategy within 10 years. Because this cost-equal time period is well within the median life expectancy for such a patient population, these findings could have important public health implications and require testing in a full-scale prognosis trial. We anticipate that over the patients' life expectancy, early revascularization is likely to become either cost-neutral or cost-effective.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034658054

Download citation: RISBibTeXText


Related references

Cost estimates for treatment of cardiac ischemia (from the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). American Journal of Cardiology 84(11): 1311-1316, 1999

Cost implications for treatment of cardiac ischemia An ancillary asymptomatic cardiac ischemia pilot study. Journal of the American College of Cardiology 27(2 Suppl. A): 186A, 1996

Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the asymptomatic cardiac ischemia pilot (ACIP) study. Journal of the American College of Cardiology 24(1): 11-20, 1994

A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. International Journal of Clinical Practice 53(1): 19-23, 1999

Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study). American Journal of Cardiology 77(15): 1302-1309, 1996

Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG. Circulation 92(9 Suppl.): Ii1-Ii7, 1995

Suppression of cardiac ischemia A comparison of randomized medical regimens in the asymptomatic cardiac ischemia pilot study. Circulation 90(4 Part 2): I28, 1994

Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review. Applied Health Economics and Health Policy 16(6): 765-778, 2018

Relation of patient characteristics to cardiac ischemia during daily life activity (an Asymptomatic Cardiac Ischemia Pilot Data Bank Study). American Journal of Cardiology 77(15): 1267-1272, 1996

Is transesophageal echocardiography the imaging modality of choice in patients with cerebral ischemia, to rule out a cardiac source of embolus? A cost-effective study. Journal of the American College of Cardiology 29(2 Suppl. A): 213A, 1997

Economic evaluation of different treatment strategies in patients with stable angina pectoris or asymptomatic myocardial ischemia on basis of results from the Asymptomatic-Cardiac-Ischemia Pilot study (ACIP). Medizinische Klinik 95(1): 1-13, 2000

Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). American Journal of Cardiology 80(11): 1395-1401, 1997

Myocardial ischemia and adverse cardiac outcomes in cardiac patients undergoing noncardiac surgery with sevoflurane and isoflurane. Sevoflurane Ischemia Study Group. Anesthesia and Analgesia 85(5): 993-999, 1997

Asymptomatic cardiac ischemia pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. Journal of the American College of Cardiology 26(3): 594-605, 1995

Evaluation of rationality in prescribing, adherence to treatment guidelines, and direct cost of treatment in intensive cardiac care unit: A prospective observational study. Indian Journal of Critical Care Medicine 18(5): 278-284, 2014